Teriflunomide news

All news on Teriflunomide (also known as Aubagio): plants, production capacities, investments and involved companies.

21 April 2026

Roche’s fenebrutinib halves RMS relapse rate to ~1 per 17 years

FENhance 1/2: the BTK inhibitor cut MRI lesion activity vs teriflunomide and showed trends to less disability; PPMS trial non‑inferior to ocrelizumab. Safety: similar LFTs; more deaths.
1 March 2026

Genentech's Fenebrutinib Shows Promise as BTK Inhibitor for MS in Phase III Study

Fenebrutinib reduced relapses by 51% in RMS, consistent with prior studies. Data will be submitted to regulators. Safety profile comparable to teriflunomide; further analysis on fatalities ongoing.

Who will be producing Teriflunomide in the future?

Find out with chemXplore Alpha

Learn more